At ASCO Day 3, AstraZeneca dominates, Takeda reveals experimental drug data, Eli Lilly serves salad. The SERD spectacle, the VERIFY study, and the dream of a better multi-cancer liquid biopsy test.

AstraZeneca India Pharma on Thursday said it has received approval from the government authority for the import, sale, and distribution of a medication used in treating non-small cell lung cancer ...

AstraZeneca is an established leader in respiratory care with a 50-year heritage and a growing portfolio of medicines in immune-mediated diseases. The company is committed to addressing the vast unmet ...

AstraZeneca’s expanding footprint in the US includes, among others: A state-of-the-art R&D centre in Kendall Square, Cambridge, Massachusett... AstraZeneca’s 9M and Q3 2024 results ...

AstraZeneca (AZN) CEO Pascal Soriot is not overly concerned about the threat of tariffs by the Trump administration on pharmaceuticals and said a more favorable corporate tax credit could motivate ...

AstraZeneca's patents covering Soliris should have expired in 2021, but the company misled the U.S. Patent and Trademark Office to obtain more patents with expiration dates "well into the future ...

AstraZeneca AZN-1.52%decrease; red down pointing triangle plans to invest $2.5 billion in China over five years to build a research-and-development center and strike deals with local biotechnology ...

AstraZeneca plans to build a $2.5 billion research and development center in Beijing, the Britain-based multinational pharmaceutical announced Friday.

AstraZeneca has shown its commitment to China amid investigations into its executives and activities, outlining plans to establish a global strategic R&D center in Beijing as part of a $2.5 ...

Eneboparatide hits primary endpoint in AstraZeneca’s Phase 3 trial for chronic hypoparathyroidism, showing significant efficacy at 24 weeks. The EU approved AstraZeneca’s Imfinzi for limited ...

The deal includes the Belgian biotech’s in-vivo cell-therapy platform, which modifies immune cells within the patient’s body, potentially increasing access to treatment and reducing costs.